BiotechTube
FluGen

FluGen

Madison, United States· Est.
flugen.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $31.4M

Overview

FluGen is a private, pre-revenue biotech founded in 2007 and based in Madison, Wisconsin, focused on revolutionizing influenza vaccination. Its lead candidate, M2SR, is an intranasal, live-attenuated vaccine platform in clinical development, designed to provide broader and more durable protection than annual shots by targeting the site of infection and inducing a multi-faceted immune response. The company has raised over $40 million, completed multiple human trials, and is exploring the platform's application against other respiratory diseases like COVID-19 and RSV. FluGen's strategy targets the significant $5 billion annual flu vaccine market, where efficacy, especially in vulnerable populations, remains a major challenge.

Infectious DiseaseRespiratory Diseases

Technology Platform

M2SR (M2-deficient Single Replication) – a live-attenuated, intranasal, replication-deficient influenza vaccine platform designed to stimulate broad mucosal, humoral, and cellular immunity for supra-seasonal protection.

Funding History

15
Total raised:$31.4M
Grant$350K
Grant$350K
Grant$1.3M
Grant$1.3M

Opportunities

The $5B+ annual flu vaccine market has a clear need for more effective, broad-spectrum vaccines, especially for vulnerable populations.
The M2SR platform's intranasal delivery and potential for supra-seasonal protection could differentiate it from current standards of care.
Platform expansion into other major respiratory diseases like COVID-19 and RSV represents significant additional market potential.

Risk Factors

High clinical development risk: the novel M2SR platform must prove superior efficacy and safety in late-stage trials.
Intense competition from large pharma and other biotechs pursuing next-gen and universal flu vaccines.
As a pre-revenue private company, FluGen faces ongoing financial risk and will need to raise substantial capital to fund advanced trials and operations.

Competitive Landscape

FluGen competes in the crowded influenza vaccine market dominated by giants like Sanofi, Seqirus (CSL), and GSK. It directly challenges AstraZeneca's intranasal FluMist and is among many biotechs (e.g., Moderna, Pfizer with mRNA, BiondVax, Vaxart) developing novel flu vaccines aiming for broader protection. Its key differentiator is the single-replication, M2-deficient design aimed at balancing immunogenicity and safety.

More companies in Biologics / Biosimilars →More companies in United States →